InsiderClue
Stocks · Health care · Biological Products, (No Diagnostic Substances)

Pelthos Therapeutics Inc.

PTHS Clue Score29
United States Fiscal year ends December CIK 0001919246
$20.50 +0.00% Close, 9 Oct 2026
Alert on the numbers Alert on insider trades
Price $20.50 −18.00% Close, 9 Oct 2026

Closing prices at the end of each trading day, from 16 Feb 2024. Not a live quote. Adjusted for share splits, so the line has no step at a split; dividends are not added back.

Revenue and profit

What the business sells, and what is left of it. Point at a year for the detail.
RevenueOperating incomeNet income
Fiscal year 2022Operating income−2.3Net income−2.5Fiscal year 2023Operating income−6.9Net income−7.4EPS, diluted−5.78Fiscal year 2024Revenue0.0Operating income−7.6Net income−8.0EPS, diluted−14.27Fiscal year 2025Revenue16.8Operating income−32.4Net income−43.3EPS, diluted−23.04
FY2022FY2023FY2024FY2025
Revenue n/a n/a 0.0 16.8
Growth
Operating income −2.3 −6.9 −7.6 −32.4
Net income −2.5 −7.4 −8.0 −43.3
Growth
EPS, diluted n/a −5.78 −14.27 −23.04

Margins

How much of each dollar of revenue it keeps. Point at a year for the detail.
Operating marginNet margin
Fiscal year 2022Fiscal year 2023Fiscal year 2024Fiscal year 2025Operating margin−193.1%Net margin−257.9%Free cash flow margin−135.1%
FY2022FY2023FY2024FY2025
Operating margin n/a n/a n/a −193.1%
Net margin n/a n/a n/a −257.9%
Free cash flow margin n/a n/a n/a −135.1%

Cash flow

The cash the business makes, what it reinvests, and what it hands back. Point at a year for the detail.
Operating cash flowCapital expenditureFree cash flow
Fiscal year 2022Operating cash flow−1.6Fiscal year 2023Operating cash flow−1.0Fiscal year 2024Operating cash flow−5.8Capital expenditure0.0Free cash flow−5.8Buybacks−0.1Fiscal year 2025Operating cash flow−22.6Capital expenditure−0.1Free cash flow−22.7Buybacks0.0
FY2022FY2023FY2024FY2025
Operating cash flow −1.6 −1.0 −5.8 −22.6
Capital expenditure n/a n/a 0.0 −0.1
Free cash flow n/a n/a −5.8 −22.7
Growth
Buybacks n/a n/a −0.1 0.0

Balance sheet

What it holds against what it owes, at each year end. Point at a year for the detail.
Cash
Fiscal year 2022Cash0.1Shareholders’ equity−3.7Fiscal year 2023Cash0.1Shareholders’ equity−6.4Fiscal year 2024Cash0.5Shareholders’ equity−2.7Fiscal year 2025Cash18.0Shareholders’ equity38.9
FY2022FY2023FY2024FY2025
Cash 0.1 0.1 0.5 18.0
Shareholders’ equity −3.7 −6.4 −2.7 38.9

In millions of USD, except per-share figures and ratios. Fiscal years, as last filed with the SEC.

Financial statements FY2025 · 10-K

Ratios

Percentages worked out from the filed figures; debt to equity in times. Fiscal years ending December, each column as last filed with the SEC.
Click a line to chart it
Fiscal year FY2022 31 Dec 2022 FY2023 31 Dec 2023 FY2024 31 Dec 2024 FY2025 31 Dec 2025
Margins
n/a n/a n/a −193.1%
n/a n/a n/a −301.9%
n/a n/a n/a −257.9%
n/a n/a n/a −135.1%
Spending
n/a n/a n/a 7.3%
n/a n/a n/a 252.8%
n/a n/a n/a 0.6%
Returns
n/a n/a n/a −111.4%
−4,464.2% −7,657.1% −581.1% −33.2%
Balance and payout
6,830.1% 6,785.8% 298.2% 70.2%